Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
Psychopharmacology|September 30, 2024
The ultrasonic vocalization (USV) syllable profile during neonatal opioid withdrawal and a kappa opioid receptor component to increased USV emissions in female miceKelly K Wingfield, Teodora Misic, Kaahini Jain, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
The ultrasonic vocalization (USV) syllable profile during neonatal opioid withdrawal and a kappa opioid receptor component to increased USV emissions in female miceKelly K Wingfield, Teodora Misic, Kaahini Jain, et al.
Lancet (London, England)|June 9, 2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
European Urology|July 27, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 StudyElizabeth R Plimack, Thomas Powles, Viktor Stus, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Scientific Reports|February 27, 2026
Development and characterization of an inducible Tensin1 deficient transgenic murine modelKsenija Bernau, Kelsey Holbert, Ivy S McDermott, et al.
CNS Drug Reviews|June 5, 2004
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disordersLynne E Rueter, David J Anderson, Clark A Briggs, et al.
Pageof 20